

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
FILING UNDER 37 C.F.R. 1.53(b)**

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL443984135US
Date of Deposit March 22, 2000

JC525 U.S. PRO
09/533559
03/22/00



Sir:

This is a request for filing a **continuation-in-part** application under 37 C.F.R. 1.53(b) of

Applicant(s): Berka *et al.*

Title: Methods For Monitoring Multiple Gene Expression

370 pages of specification 0 sheets of formal drawings 2803 pages of Sequence Listing
3 sheets of Declaration and Power of Attorney

The filing fee is calculated as follows:

Basic Fee:	\$690.00
Total Claims: $20 - 20 = 0 \times 18 =$	\$0
Independent Claims: $3 - 3 = 0 \times 78 =$	\$0
Total Fee:	\$690.00


This application is a continuation-in-part of application no. 09/273,623 filed on March 22, 1999 and claims priority under 35 U.S.C. 119, the contents of which are fully incorporated herein by reference.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$690, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: March 22 2000

Respectfully submitted,



Robert L. Starnes, Reg. No. 41,324
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, New York 10017
(212) 867-0123

jc610 U.S. PTO
03/22/00

03-24-00

A

PATENT

Attorney Docket No.: 5849.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
"Methods For Monitoring Multiple Gene Expression"
Applicants: Berka *et al.*

jc525 U.S. PTO
09/533559
03/22/00

Sir:

Express Mail Label No.: EL443984135US

Date of Deposit: March 22, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Executed Combined Declaration and Power of Attorney
4. Preliminary Amendment
5. Assignment
6. Recordation
7. Sequence Listing
8. Computer Readable Sequence Listing
9. Verified Statement
10. Information Disclosure Statement Transmittal (in duplicate)
11. Information Disclosure Statement
12. Copy of References

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Seleste A. Buriani
(Name of person mailing papers or fees)

Seleste A. Buriani
(Signature of person mailing papers or fees)

Mailing Address:

Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123